Top-Rated Olanzapine Brands for Optimal Mental Health Care

Olanzapine, a widely prescribed antipsychotic medication, has seen a surge in popularity due to its effectiveness in treating conditions like schizophrenia and bipolar disorder. With a variety of manufacturers producing this medication, patients and healthcare professionals often seek guidance on which brands to consider. Factors such as efficacy, side effects, and affordability play crucial roles in determining the best choice for each individual's needs. To explore a comprehensive list of leading olanzapine brands and learn more about their specific attributes, continue reading below.

Illustration of olanzapine

Best brands of olanzapine in 2025

Zyprexa

Zyprexa, produced by Eli Lilly and Company, is a leading brand in the olanzapine market, known for its efficacy in treating schizophrenia and bipolar disorder. In 2021, the North American market, where Zyprexa dominates, accounted for more than two-fifths of the global olanzapine market share. The FDA approved Zyprexa for adolescent indications in 2009, expanding its treatment scope to include schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years. Zyprexa's sales have shown significant growth, such as a 14% increase in the first quarter of 2000 compared to the previous year. The brand continues to be a major player, with the Asia-Pacific region expected to be the fastest-growing market for olanzapine in the coming years.

Oliza

Olanzapine, marketed under the brand name Oliza by Intas Pharmaceuticals, is a highly effective atypical antipsychotic medication used to treat schizophrenia, mania, and depression. Oliza is available in various formulations, including tablets and injectables, ensuring versatile treatment options. The global olanzapine market, which includes Oliza, is projected to grow at a CAGR of 2.3% from 2022 to 2031, reaching a market size of $2.2 billion by 2031. Oliza's oral segment accounts for the largest revenue due to high patient compliance and convenience, while the parenteral segment is expected to register the highest growth rate. The medication's efficacy in managing symptoms of psychiatric disorders has made it a significant player in the mental health treatment landscape.

Olnex

Olanzapine, marketed by Sun Pharmaceutical Industries under various brands, is a highly effective atypical antipsychotic used primarily for treating schizophrenia and bipolar disorder. Sun Pharma, the fourth largest specialty generic pharmaceutical company globally, ensures high-quality and affordable medicines, with olanzapine being one of its key products. In 2021, the oral segment of olanzapine, which includes Sun Pharma's offerings, accounted for nearly three-fourths of the global market share. Sun Pharma's global revenues reached $5.4 billion, with a significant portion attributed to its neuro-psychiatry segment. The company's extensive distribution network spans over 100 countries, making its olanzapine products widely accessible. For more information about Sun Pharmaceutical Industries, you can visit their official website.

Olmax

Olanzapine, marketed under various brands including Olmax by Cipla, is a widely used antipsychotic medication for treating schizophrenia, bipolar I disorder, and depression. Cipla, a renowned pharmaceutical company, ensures high-quality production of Olmax, which has been valued for its efficacy and patient compliance. The global olanzapine market, including Olmax, is projected to grow at a CAGR of 2.3% from 2022 to 2031, reaching $2.2 billion by 2031. Olmax, like other olanzapine formulations, exhibits high oral bioavailability and linear pharmacokinetics, making it a reliable choice for patients. With its extensive distribution network, Cipla's Olmax is accessible through various channels, including hospital pharmacies and retail stores.

Oleanz

Olanzapine, particularly the brand offered by Sun Pharmaceutical Industries, is renowned for its high quality and efficacy in treating schizophrenia and bipolar disorder. This medication, approved by the FDA for patients over 13 years old, has shown significant effectiveness in managing symptoms such as hallucinations, delusions, and disorganized behavior, with a steady-state plasma concentration achieved in about one week and a peak plasma concentration of 156.9 ng/ml approximately 6 hours after oral administration. The oral segment of olanzapine, which includes Sun Pharmaceutical's tablets, accounted for nearly three-fourths of the global market share in 2021. The drug is extensively metabolized by the liver, primarily by CYP1A2, and is 93% bound to plasma proteins. With a projected market growth of 2.3% CAGR from 2022 to 2031, Sun Pharmaceutical's olanzapine remains a leading choice in the antipsychotic market. For more details, visit their olanzapine product page.

Relprevv

ZYPREXA RELPREVV, developed by Eli Lilly and Company, is a highly effective extended-release formulation of olanzapine, primarily used to treat schizophrenia and bipolar disorder. This intramuscular injection corresponds to oral olanzapine doses, with a 150 mg dose every 2 weeks or 300 mg every 4 weeks approximating 10 mg/day of oral olanzapine. The product has shown a similar safety profile to oral olanzapine, with weight gain being the most commonly reported adverse event. In clinical studies, there were no significant differences in metabolic changes between ZYPREXA RELPREVV and oral olanzapine. The global olanzapine market, including ZYPREXA RELPREVV, is projected to grow at a CAGR of 2.3% from 2022 to 2031, reaching $2.2 billion by 2031. For comprehensive details, you can refer to the ZYPREXA RELPREVV HCP Training document.

Olzapin

Olanzapine, produced by Torrent Pharmaceuticals, is a leading antipsychotic medication used primarily for treating schizophrenia and bipolar disorder. With a global market size projected to reach $2.2 billion by 2031 and a CAGR of 2.3%, Torrent Pharmaceuticals stands out as a significant player, especially in regions like North America and the Asia-Pacific, where the demand for olanzapine is increasing due to rising mental health awareness. The oral segment of olanzapine, which accounts for the largest revenue, is a key area of focus for Torrent Pharmaceuticals, given its high patient compliance and convenience. The company's strong technical capabilities and international accreditations further enhance its position in the market. Torrent Pharmaceuticals has a significant presence in over 50 countries, including a leading market share in Brazil and Germany. For more information about their offerings, visit their official website.

Olzimax

Olanzapine, particularly the brand Olzimax by Micro Labs, is renowned for its efficacy in treating psychiatric disorders such as schizophrenia and bipolar disorder. With a significant market share, Olzimax has been a preferred choice due to its high bioavailability and compliance-friendly formulations, including tablets and orally disintegrating tablets. The global olanzapine market, which includes Olzimax, was valued at $1.8 billion in 2021 and is projected to reach $2.2 billion by 2031, growing at a CAGR of 2.3%. In 2021, the oral segment, which includes Olzimax tablets, captured nearly three-fourths of the global olanzapine market share. The market's growth is driven by the rise in incidence of mental disorders and increasing government support for mental health infrastructure.

Zylene

Zylene, a brand by Hetero Healthcare, is a prominent producer of olanzapine, a medication primarily used for treating schizophrenia and bipolar disorder. The global olanzapine market, which includes brands like Zylene, was valued at $1.8 billion in 2021 and is projected to reach $2.2 billion by 2031, growing at a CAGR of 2.3% from 2022 to 2031. North America, where Zylene is widely available, held more than two-fifths of the global market share in 2021. The market growth is driven by the increasing incidence of mental health disorders and the surge in awareness toward mental health. However, side effects such as weight gain and increased cholesterol levels are factors that can hamper market growth. For more information, visit the Zylene product page on the Hetero Healthcare website.

Olapin

Olanzapine, marketed under various brands including Olapin by Macleods Pharmaceuticals, is a highly effective antipsychotic medication used to treat schizophrenia, bipolar disorder, and major depressive disorder. Olapin, as a generic version of olanzapine, offers a cost-effective alternative without compromising on efficacy. The global olanzapine market, which includes brands like Olapin, is projected to grow at a CAGR of 2.3% to 3.4% from 2022 to 2031, reaching a market size of approximately $2.2 billion to $3.97 billion by the end of the forecast period. North America and Asia-Pacific regions are expected to be significant contributors to this growth, driven by increasing mental health awareness and expanding healthcare infrastructure. Olapin's availability in various formulations, such as tablets and orally disintegrating tablets, enhances patient compliance and convenience.